Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6012 in Stable Atherosclerotic Cardiovascular Disease
NCT03773172Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human lecithin-cholesterol acyltransferase in atherosclerotic cardiovascular disease (ASCVD), sponsored by Columbia University. Started Jan 2019; status: terminated.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT03773172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773172.